Skip to main content
SpringerLink
Log in

Correlations between vitronectin, miR-520, and miR-34 in patients with stenosis of coronary arteries

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

In-stent restenosis usually occurs by platelet activation, neointima formation, VSMC migration, and proliferation in the position of the vessel stent. The monocytes have a magnificent role in neointimal hyperplasia since these cells recruit to the site of vessel injury through chemokines and other secretion proteins. This study is focused on the investigation of vitronectin, miR-193, miR-34, and miR-520 expression levels in PBMCs isolated from stenosed patients.

Methods

A total of sixty subjects undergoing coronary artery angiography containing patients with stent no restenosis (n = 20), in-stent restenosis (n = 20), and healthy participants (n = 20) participated in the study. The vitronectin, miR-193, miR-34, and miR-520 expression levels were measured by the RT-qPCR technique. Data were analyzed by SPSS software.

Results

The vitronectin, miR-34, and miR-520 expression levels changed significantly in patients with vessel in-stent restenosis (p = 0.02, p = 0.02, and p = 0.01, respectively). Furthermore, there were inverse correlations between the expression levels of vitronectin gene and miR-34 (r =  – 0.44, p = 0.04) as well as miR-520 (r =  – 0.5, p=0.01).

Conclusions

The molecular events in the vessel stenosis may be affected by targeting vitronectin with miR-520 and miR-34.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

It is presented on the request from the corresponding author.

References

  1. Kim MJ, Jung SK (2020) Nutraceuticals for prevention of atherosclerosis: targeting monocyte infiltration to the vascular endothelium. J Food Biochem 44(3):e13200

    PubMed  Google Scholar 

  2. Wu M-Y et al (2017) New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci 18(10):2034

    Article  Google Scholar 

  3. Geovanini GR, Libby P (2018) Atherosclerosis and inflammation: overview and updates. Clin Sci 132(12):1243–1252

    Article  CAS  Google Scholar 

  4. Spadaccio C, Benedetto U (2018) Coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in the treatment of multivessel coronary disease: quo vadis?—a review of the evidences on coronary artery disease. Annals of cardiothoracic surgery 7(4):506

    Article  Google Scholar 

  5. Malik TF, Tivakaran VS (2019) Percutaneous transluminal coronary angioplasty (PTCA). StatPearls, Treasure Island

    Google Scholar 

  6. Jukema JW et al (2012) Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 9(1):53

    Article  CAS  Google Scholar 

  7. Su Y-C, Riesbeck K (2018) Vitronectin. The complement facts book. Elsevier, Amsterdam, pp 351–360

    Chapter  Google Scholar 

  8. Garg N et al (2010) Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost 8(8):1847–1854

    Article  CAS  Google Scholar 

  9. Luo M et al (2017) Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin. J Thromb Haemost 15(12):2451–2460

    Article  CAS  Google Scholar 

  10. Grad E et al (2018) The role of monocyte subpopulations in vascular injury following partial and transient depletion. Drug Deliv Trans Res 8(4):945–953

    Article  CAS  Google Scholar 

  11. Yin R-X, Yang D-Z, Wu J-Z (2014) Nanoparticle drug-and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics 4(2):175

    Article  CAS  Google Scholar 

  12. Shafiee S et al (2017) Vitronectin and urokinase-type plasminogen activator gene expression levels are increased in patients with coronary artery in-stent restenosis. Int J Angiol 26(4):218

    Article  CAS  Google Scholar 

  13. Kakavandi N et al (2021) Prostaglandin E2 (PGE2) synthesis pathway is involved in coronary artery stenosis and restenosis. Gene 765:145131

    Article  CAS  Google Scholar 

  14. Rezaee S et al (2020) COX and PTGDS gene expression levels in PGD2 synthesis pathway are correlated with miR-520 in patients with vessel restenosis. Endocr, Metab Immune Disord-Drug Targets 20(9):1514–1522

    Article  CAS  Google Scholar 

  15. Collado A et al (2021) MicroRNA: a mediator of diet-induced cardiovascular protection. Curr Opin Pharmacol 60:183–192

    Article  CAS  Google Scholar 

  16. Jiao Y et al (2021) MicroRNA-520c-3p suppresses vascular endothelium dysfunction by targeting RELA and regulating the AKT and NF-κB signaling pathways. Journal Physiol Biochem 77(1):47–61

    Article  CAS  Google Scholar 

  17. Wu Z et al (2020) MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4. Pulm Circ 10(4):2045894020974919

    PubMed  PubMed Central  Google Scholar 

  18. Badacz R et al (2021) Expression of miR-1-3p, miR-16-5p and miR-122-5p as possible risk factors of secondary cardiovascular events. Biomedicines 9(8):1055

    Article  CAS  Google Scholar 

  19. Fukuda D et al (2004) Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 43(1):18–23

    Article  Google Scholar 

  20. Fishman RF et al (1992) Long-term results of directional coronary atherectomy: predictors of restenosis. J Am Coll Cardiol 20(5):1101–1110

    Article  CAS  Google Scholar 

  21. Gürlek A et al (1995) Restenosis after transluminal coronary angioplasty: a risk factor analysis. Eur J Cardiovasc Prev Rehabil 2(1):51–55

    Article  Google Scholar 

  22. Violaris AG, Melkert R, Serruys PW (1994) Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. Circulation 90(5):2267–2279

    Article  CAS  Google Scholar 

  23. Yaghoubi A et al (2015) Correlation of serum levels of vitronectin, malondialdehyde and Hs-CRP with disease severity in coronary artery disease. J Cardiovasc Thorac Res 7(3):113

    Article  Google Scholar 

  24. Ekmekci H et al (2002) Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 14(3):221–225

    Article  CAS  Google Scholar 

  25. Chu Y, Bucci JC, Peterson CB (2020) Identification of a PAI-1‐binding site within an intrinsically disordered region of vitronectin. Protein Sci 29(2):494–508

    Article  CAS  Google Scholar 

  26. Liu P, Wilson MJ (2012) miR-520c and miR-373 target mTOR and SIRT1, activate the Ras/Raf/MEK/Erk pathway and NF-κB, with up-regulation of MMP9 in human fibrosarcoma cells. J Cell Physiol 227(2):867

    Article  CAS  Google Scholar 

  27. Yi M et al (2016) miR-520e regulates cell proliferation, apoptosis and migration in breast cancer. Oncol Lett 12(5):3543–3548

    Article  CAS  Google Scholar 

  28. Choe N et al (2015) The microRNA miR-34c inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by targeting stem cell factor. Cell Signal 27(6):1056–1065

    Article  CAS  Google Scholar 

  29. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17(2):193–199

    Article  CAS  Google Scholar 

  30. Lin JM et al (2021. May) BCL-6 promotes the methylation of miR‐34a by recruiting EZH2 and upregulating CTRP9 to protect ischemic myocardial injury. BioFactors 47(3):386–402

    Article  CAS  Google Scholar 

  31. Gacoń J et al (2018) Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: a four-year prospective study. Kardiol Polska 76(2):362–369

    Article  Google Scholar 

Download references

Funding

The part of the work was supported by IUMS (No. 14442).

Author information

Authors and Affiliations

  1. Clinical Biochemistry Department, Faculty of Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

    Ghasem Ghasempour, Ali Akbar Soleimani, Borhan Rahimi & Mohammad Najafi

  2. Clinical Biochemistry Department, Faculty of Medical Sciences, Urmia University of Medical Sciences, Tehran, Iran

    Farhad Shaikhnia

Authors
  1. Ghasem Ghasempour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farhad Shaikhnia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Akbar Soleimani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Borhan Rahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Najafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MN designed the study; GG, FS, BR and AS evaluated the gene and protein expression levels. MN and GG analyzed the data.

Corresponding author

Correspondence to Mohammad Najafi.

Ethics declarations

Ethical approval

It was approved by the Committee on the Ethics of IUMS (IR.IUMS.FMD.REC.1397.341).

Research involving human and animal participants

All procedures performed in studies involving human participants were following the ethical standards of the institutional research committee with the 1964 Helsinki declaration.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghasempour, G., Shaikhnia, F., Soleimani, A.A. et al. Correlations between vitronectin, miR-520, and miR-34 in patients with stenosis of coronary arteries. Mol Biol Rep 48, 7913–7920 (2021). https://doi.org/10.1007/s11033-021-06821-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06821-z

Keywords

Search

Navigation